AnHorn Medicines is a novel drug discovery platform company with a strong pipeline, offering therapies that target and degrade disease-causing proteins. Our mission is to develop new class of BIGPRO® (Bi-functional liGand induced PROteolysis) drugs under the foundation of Targeted Protein Degradation (TPD), to address a broad range of life-threatening and life-impairing diseases.

We focus on novel therapies for cancer, neurodegeneration, and aging diseases by applying AnHorn’s proprietary AIMCADD®, an AI-enabled platform screening high potential drug candidates. We are turning innovation into new therapeutics – new opportunities to target difficult-to-treat and drug resisting diseases.

AnHorn’s Drug Development Strategy:

．Focuses on discovering BIGPRO® new drugs

．Go beyond next generation of targeted protein degradation by developing novel E3 ligase and its ligand

．Expands unexplored therapeutic opportunity in undruggable targets

．Establish a multilayer patent protection framework for projects